Eli Lilly’s weight-loss pill, orforglipron, shows promising results in trials, offering a needle-free alternative to injectables like Ozempic and Mounjaro. In a major study, people who took the drug ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Hyderabad: Sales of weight-loss drugs Wegovy by Danish pharmaceutical giant Novo Nordisk and Mounjaro by U.S.-based Eli Lilly ...

Eli Lilly is seeing strong growth from its weight loss drugs. Investors are nervous about tariffs on drugs and weak data from ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities ...

FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of ...

Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight ...

A new weight loss pill has been shown to help slimmers lose around 12 per cent of their body weight over 72 weeks. Alongside ...

Eli Lilly's (LLY) recent earnings and GLP-1 trial results shook the biopharma market this week. Courtney Breen, Bernstein ...

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...